CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.3 EUR | -20.96% |
|
-25.20% | -65.67% |
| Jun. 14 | Carmat: under pressure after equitization operation | CF |
| May. 21 | CARMAT : Invest Securities remains Buy, lowers its target | CF |
| Sales 2024 * | 20.98M 22.45M | Sales 2025 * | 43.62M 46.68M | Capitalization | 79.24M 84.81M |
|---|---|---|---|---|---|
| Net income 2024 * | -39M -41.74M | Net income 2025 * | -30M -32.11M | EV / Sales 2024 * | 6.84 x |
| Net Debt 2024 * | 64.27M 68.78M | Net Debt 2025 * | 106M 113M | EV / Sales 2025 * | 4.24 x |
| P/E ratio 2024 * |
-1.67
x | P/E ratio 2025 * |
-2.33
x | Employees | 182 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
| 1 day | -20.96% | ||
| 1 week | -25.20% | ||
| Current month | -26.98% | ||
| 1 month | -45.88% | ||
| 3 months | -43.35% | ||
| 6 months | -60.14% | ||
| Current year | -65.67% |
1 week
2.29
3.07
1 month
2.294.28
Current year
2.297.72
1 year
2.299.99
3 years
2.2931.70
5 years
2.2936.00
10 years
2.2996.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | 53 | 16-08-31 |
| Director of Finance/CFO | - | 18-12-11 | |
Marc Grimmé
CTO | Chief Tech/Sci/R&D Officer | - | 08-06-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Director/Board Member | 61 | 21-05-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 2.3 | -20.96% | 473,085 |
| 24-06-13 | 2.91 | -2.35% | 50,570 |
| 24-06-12 | 2.98 | 0.00% | 57,775 |
| 24-06-11 | 2.98 | -1.00% | 51,994 |
| 24-06-10 | 3.01 | -2.11% | 100,851 |
Real-time Euronext Paris, June 14, 2024 at 11:35 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.3
EUR
Average target price
12.32
EUR
Spread / Average Target
+435.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -65.67% | 108M | |
| +15.20% | 131B | |
| -7.32% | 11.25B | |
| -11.58% | 7.84B | |
| +41.65% | 5.72B | |
| -18.05% | 4.97B | |
| +7.99% | 3.44B | |
| -19.96% | 2.46B | |
| -15.76% | 2.02B | |
| -16.68% | 1.87B |
- Stock Market
- Equities
- ALCAR Stock
